Co-morbidities

HFA 23: DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF

Ross Campbell,

Watch time: 3m 56s
HFA 23 Late-breaker Discussion: The PARAGLIDE-HF Trial

Robert Mentz, Harriette Van Spall,

Watch time: 5m 48s

Fausto J Pinto, John Spertus, , et al

Watch time: 16h 19m 46s (19 videos)
View from the Thoraxcenter: ACC.23 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 33m 36s
ACC 23 Late-breaking Discussion: The COORDINATE-Diabetes Trial

Harriette Van Spall, Neha Pagidipati, Christopher B Granger, et al

Watch time: 17m 32s
Radcliffe & CardioNerds @AHA22: IRONMAN: Intravenous Ferric Derisomaltose in HF With Reduced EF

Rawan Amir, Paul Kalra,

Watch time: 18m 58s

Shelley Zieroth, Andrew Frankel, , et al

Radcliffe & CardioNerds @AHA22: EMPA-Kidney: Empagliflozin & CV Outcomes in Patients with Chronic Kidney Disease

Kate Wilcox, David Preiss,

Watch time: 18m 1s
Insights from EMPA-Kidney: Methodology, Data & Impact

Kate Wilcox, David Preiss,

Watch time: 38m 47s

Paul Kalra,

Watch time: 12m 41s (2 videos)

Christiane Angermann, Javed Butler, Clyde W Yancy, et al

Watch time: 1h 5m 18s (6 videos)

Giuseppe Rosano, Richard Henry P Tiongco, Rungroj Krittayaphong, et al

Christiane Angermann, Javed Butler, Clyde W Yancy, et al

Watch time: 1h 5m 18s (6 videos)

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

Watch time: 7h 25m 37s (31 videos)

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

Watch time: 53m 14s (5 videos)
The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

Watch time: 36m 12s (5 videos)

Shelley Zieroth, Andrew Frankel, , et al

Fausto J Pinto, John Spertus, , et al

Watch time: 16h 19m 46s (19 videos)

Paul Kalra,

Watch time: 12m 41s (2 videos)
The PRESERVED-HF Study

Mikhail Kosiborod,

Watch time: 12m 4s

Rami Khayat , Andrew Pederzoli , William T Abraham ,

Saumil R Shah , Sergio Waxman , William H Gaasch ,

Giuseppe Rosano, Richard Henry P Tiongco, Rungroj Krittayaphong, et al

ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

Watch time: 11m 30s

About

Comorbidities frequently accompany chronic heart failure, contributing to increased morbidity and mortality, and an impaired quality of life. Extreme comorbidity is significantly more common in patients with chronic heart failure due to left ventricular systolic dysfunction. The efficient management of such complexity requires the integration of general and specialist expertise.

Media

HFA 23 Late-breaker Discussion: The PARAGLIDE-HF Trial

Robert Mentz, Harriette Van Spall,

Watch time: 5m 48s

Fausto J Pinto, John Spertus, , et al

Watch time: 16h 19m 46s (19 videos)
ACC 23 Late-breaking Discussion: The COORDINATE-Diabetes Trial

Harriette Van Spall, Neha Pagidipati, Christopher B Granger, et al

Watch time: 17m 32s
Radcliffe & CardioNerds @AHA22: IRONMAN: Intravenous Ferric Derisomaltose in HF With Reduced EF

Rawan Amir, Paul Kalra,

Watch time: 18m 58s

Shelley Zieroth, Andrew Frankel, , et al

Paul Kalra,

Watch time: 12m 41s (2 videos)

Christiane Angermann, Javed Butler, Clyde W Yancy, et al

Watch time: 1h 5m 18s (6 videos)

Giuseppe Rosano, Richard Henry P Tiongco, Rungroj Krittayaphong, et al

EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

Watch time: 22m 15s
Association Between AID/FID with Incident CV Disease and Mortality

Benedikt Schrage,

Watch time: 5m 31s
The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

Watch time: 36m 12s (5 videos)
The PRESERVED-HF Study

Mikhail Kosiborod,

Watch time: 12m 4s

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

Watch time: 7h 25m 37s (31 videos)
ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

Watch time: 15m 45s
ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

Watch time: 11m 30s

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

Watch time: 53m 14s (5 videos)

Media

HFA 23: DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF

Ross Campbell,

Watch time: 3m 56s
HFA 23 Late-breaker Discussion: The PARAGLIDE-HF Trial

Robert Mentz, Harriette Van Spall,

Watch time: 5m 48s

Fausto J Pinto, John Spertus, , et al

Watch time: 16h 19m 46s (19 videos)
View from the Thoraxcenter: ACC.23 Late-breaking Science Wrap Up

Nicolas M Van Mieghem, Joost Daemen,

Watch time: 33m 36s
ACC 23 Late-breaking Discussion: The COORDINATE-Diabetes Trial

Harriette Van Spall, Neha Pagidipati, Christopher B Granger, et al

Watch time: 17m 32s
Radcliffe & CardioNerds @AHA22: IRONMAN: Intravenous Ferric Derisomaltose in HF With Reduced EF

Rawan Amir, Paul Kalra,

Watch time: 18m 58s

Shelley Zieroth, Andrew Frankel, , et al

Radcliffe & CardioNerds @AHA22: EMPA-Kidney: Empagliflozin & CV Outcomes in Patients with Chronic Kidney Disease

Kate Wilcox, David Preiss,

Watch time: 18m 1s
Insights from EMPA-Kidney: Methodology, Data & Impact

Kate Wilcox, David Preiss,

Watch time: 38m 47s

Paul Kalra,

Watch time: 12m 41s (2 videos)

Christiane Angermann, Javed Butler, Clyde W Yancy, et al

Watch time: 1h 5m 18s (6 videos)

Giuseppe Rosano, Richard Henry P Tiongco, Rungroj Krittayaphong, et al

HF 22: SCD Risk Protection for Newly Diagnosed HF Patients

José González-Costello,

Watch time: 2m 16s
EMPATROPISM FE: Effects of Empagliflozin on iron metabolism in non-diabetic

Christiane Angermann,

Watch time: 22m 15s
Association Between AID/FID with Incident CV Disease and Mortality

Benedikt Schrage,

Watch time: 5m 31s
The PRESERVED-HF Study – Main Study Presentation and Peer-to-peer Discussion

Mikhail Kosiborod, Dalane W Kitzman,

Watch time: 36m 12s (5 videos)
The PRESERVED-HF Study

Mikhail Kosiborod,

Watch time: 12m 4s
EP 54: 5 Trials that will change your practice: Review of ESC 21 with Dr Purvi Parwani

Ankur Kalra, Purvi Parwani,

Listen time: 1h

Stefan Anker, Shelley Zieroth, Andrew JS Coats, et al

Watch time: 7h 25m 37s (31 videos)
ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod,

Watch time: 15m 45s
ACC 2021 Discussion: The LIFE Trial

Harriette Van Spall, Douglas L Mann,

Watch time: 11m 30s
ACC 2021 Discussion: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF, Including HFpEF

Deepak L Bhatt, Harriette Van Spall,

Watch time: 16m 6s

Shelley Zieroth, Martin R Cowie, Javed Butler, et al

Watch time: 53m 14s (5 videos)
AHA 2020: EMPA-TROPISM Trial Results — Dr Juan Badimon

Watch time: 6m 47s
AHA 2020 Discussion: The SOLOIST-WHF Study

Harriette Van Spall, Deepak L Bhatt,

Watch time: 18m 37s
ESC 2020: Commentary on the EMPEROR-Reduced Study — Dr Giuseppe Galati

Giuseppe Galati,

Watch time: 10m 13s
HFA 2020: Dapagliflozin and diuretic use in patients with HFrEF in DAPA-HF

Alice Jackson,

Watch time: 6m 56s
HFA 2020: Prospective analysis of DAPA-HF

ACC 2019: EMPRISE Study

Elisabetta Patorno,

Watch time: 4m 6s

Aarti Asnani,

Articles

COVID-19 Pandemic and Cardiovascular Disease

Aniket S Rali

,

Andrew J Sauer

,

Published:

25 March 2020

Citation:

US Cardiology Review 2020;14:e01.

DOI:

https://doi.org/10.15420/usc.2020.14
  • Views: Views 1017
  • Downloads: Downloads 30
  • Citations: 10

Impact of Atrial Septal Defect on Hemodynamics

Saumil R Shah

,

Sergio Waxman

,

William H Gaasch

,

Citation:

US Cardiology Review 2017;11(2):72–4.

DOI:

https://doi.org/10.15420/ucs.2017:9:2
  • Views: Views 4353
  • Downloads: Downloads 23
  • Citations: 3

Transvenous Phrenic Nerve Stimulation - A Novel Therapy for Central Sleep Apnea in Heart Failure

Sitaramesh Emani

,

William T Abraham

,

Citation:

US Cardiology 2012;9(1):53-6

DOI:

https://doi.org/10.15420/usc.2012.9.1.53
  • Views: Views 912
  • Downloads: Downloads 3
  • Citations: 1

Central Sleep Apnea in Heart Failure

Rami Khayat

,

Andrew Pederzoli

,

William T Abraham

,

Citation:

US Cardiology 2009;6(2):72–8

DOI:

https://doi.org/10.15420/usc.2009.6.2.72
  • Views: Views 5454
  • Downloads: Downloads 8
  • Citations: 4